Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00134693
Registration number
NCT00134693
Ethics application status
Date submitted
24/08/2005
Date registered
25/08/2005
Date last updated
31/07/2017
Titles & IDs
Public title
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
Query!
Scientific title
A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship
Query!
Secondary ID [1]
0
0
RA1104046
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Prednisolone
Treatment: Drugs - SB-681323
Treatment: Drugs: Prednisolone
Treatment: Drugs: SB-681323
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Analysis for C-Reactive protein (CRP) levels 72 hours post-dose following SB-681323
Query!
Assessment method [1]
0
0
CRP levels were compared between SB-681323 and placebo 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Query!
Timepoint [1]
0
0
Day 3 (at 72 hour)
Query!
Secondary outcome [1]
0
0
Analysis of CRP levels 24 and 48 hours post-dose following SB-681323
Query!
Assessment method [1]
0
0
CRP levels were compared between SB-681323 and placebo 24 and 48 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Query!
Timepoint [1]
0
0
Day 1 (at 24 hour) and Day 2 (at 48 hour)
Query!
Secondary outcome [2]
0
0
Analysis of Interleukin (IL)-6 levels up to 72 hours post-dose following SB-681323
Query!
Assessment method [2]
0
0
A blood sample of approximately 5 milliliter (mL) was taken for measurement of serum markers. IL-6 measurements were performed at 1 hour, 3, hours, 24 hours and 72 hours post-dose. The ratio of the dose response relationship of placebo and 7.5mg, 15mg and 25mg of SB-681323 has been presented.
Query!
Timepoint [2]
0
0
Upto Day 3 (at 1, 3, 24 and 72 hour)
Query!
Secondary outcome [3]
0
0
Number of participants with adverse events (AE) and serious adverse events (SAE)
Query!
Assessment method [3]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or require medical or surgical intervention to prevent one of the other outcomes listed in the definition above, or is an event of possible drug-induced liver injury. There were no SAEs reported in this study.
Query!
Timepoint [3]
0
0
Upto Day 3 (72 hours)
Query!
Secondary outcome [4]
0
0
Change from Baseline in vital sign systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Query!
Assessment method [4]
0
0
Supine vital signs SBP and DBP were recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.
Query!
Timepoint [4]
0
0
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Query!
Secondary outcome [5]
0
0
Change from Baseline in vital sign heart rate
Query!
Assessment method [5]
0
0
Supine vital signs (heart rate) was recorded whilst the participant was in a supine position (participant lying flat with maximum one pillow) having rested in that position for at least 10 minutes before each reading. Measurements were performed at 90 minutes, 3 hours, 24 hours and 72 hours post-dose. Baseline was defined as assessment performed pre-dose at Day 0. Change from Baseline was calculated by subtracting the Baseline value from the individual post-randomization values at the time of assessment.
Query!
Timepoint [5]
0
0
Baseline (at pre-dose Day 0) and Day 3 (at 90 minutes, 3 hour, 24 and 72 hour)
Query!
Secondary outcome [6]
0
0
Number of participants with abnormal electrocardiogram (ECG) findings
Query!
Assessment method [6]
0
0
Full 12-lead ECGs were recorded using an ECG machine that automatically calculated the pulse rate and measured PR, RR, QRS, QT, QTc(b) intervals (Bazett's correction was applied to QTc measurements). Measurements were carried out at pre-dose, 1 hour and 3 hours on Day 1. ECG findings were characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS). Data has been presented for A-NCS findings on Day 1.
Query!
Timepoint [6]
0
0
Day 1 (pre-dose, 1 hour and 3 hour)
Query!
Secondary outcome [7]
0
0
Number of participants with clinical chemistry data outside the clinical concern range
Query!
Assessment method [7]
0
0
Clinical chemistry parameters included albumin, alkaline phosphatase, alanine amino transferase, indirect bilirubin, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, potassium, lactate dehydrogenase, triglycerides. Measurements were carried out at pre-dose, 24 hours, 48 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.
Query!
Timepoint [7]
0
0
Upto Day 3 (pre-dose, 24, 48 and 72 hours
Query!
Secondary outcome [8]
0
0
Number of participants with hematology data outside the clinical concern
Query!
Assessment method [8]
0
0
Hematology parameters included eosinophils, hemoglobin, hematocrit, lymphocytes, mean corpuscle hemoglobin, mean corpuscle volume, platelet count, reticulocytes, white blood cell count (WBC). Measurements were carried out at pre-dose, 24 hours and 72 hours. Data for number of participants with values outside clinical concern range defined as high and low have been presented.
Query!
Timepoint [8]
0
0
Upto Day 3 (pre-dose, 24 and 72 hours)
Query!
Secondary outcome [9]
0
0
Number of participants with abnormal urinalysis dipstick results
Query!
Assessment method [9]
0
0
Approximately 10-20 mL mid-stream urine was collected into a sterile container and was screened by dipstick for: occult blood, proteins, ketones, glucose, red blood cells (RBC) and WBC. Sediment microscopy was performed only if any of the Multi-stick tests were abnormal. In such cases, microscopy was performed for: WBC, RBC, hyaline casts, granular casts, cellular casts. Data for number of participants with abnormal urinalysis results for positive parameters as assessed by dipstick and microscopic analysis have been presented.
Query!
Timepoint [9]
0
0
Upto Day 3 (pre-dose, 24 and 72 hours)
Query!
Secondary outcome [10]
0
0
Whole blood messenger RNA (mRNA) levels of tumor necrosis factor alpha [TNF-a], IL-8, IL-1ß and Cyclo-oxygenase-2 [COX-2] (and other genes implicated in the pathogenesis of RA or genes involved in the mode of action of the compounds administered)
Query!
Assessment method [10]
0
0
Blood samples were taken for extraction of whole blood mRNA (2 x 2.5mL PAXgene tubes). The samples were taken at the time-points pre-dose, 45 minutes, 90 minutes and 3 hours. Messenger RNA levels for various markers was measured. These markers included Prednisolone markers: DDIT4, DUSP1, FKBP5, GILZ, IL1R2, TXNIP, ZNF145 and p38 markers: COX2, IFI30, IL1b, IL6, IL8, TNF. An aliquot of mRNA was stored for later analysis of other genes associated with the pathogenesis of RA and in the mode of action of the compounds administered.
Query!
Timepoint [10]
0
0
Pre-dose, 45 minutes, 90 minutes and 3 hours on Day 1
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Must have a diagnosis of RA according to the revised 1987 criteria of the American
College of Rheumatology.
- Must have 3 or more swollen or 3 or more tender/painful joints at screening.
- Must be on stable weekly methotrexate (2.5mg - 25mg) for at least eight weeks prior to
screening.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Must not be morbidly obese.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/06/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
3/08/2006
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
77
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Darlinghurst
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Douglas
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Woolloongabba
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Daw Park
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Woodville
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Hobart
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Shenton Park
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
4814 - Douglas
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [5]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [6]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [7]
0
0
6008 - Shenton Park
Query!
Recruitment outside Australia
Country [1]
0
0
France
Query!
State/province [1]
0
0
Picardie
Query!
Country [2]
0
0
France
Query!
State/province [2]
0
0
Montpellier Cedex 5
Query!
Country [3]
0
0
Germany
Query!
State/province [3]
0
0
Baden-Wuerttemberg
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Niedersachsen
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Sachsen
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Berlin
Query!
Country [7]
0
0
Russian Federation
Query!
State/province [7]
0
0
Ekaterinburg
Query!
Country [8]
0
0
Russian Federation
Query!
State/province [8]
0
0
Moscow
Query!
Country [9]
0
0
Russian Federation
Query!
State/province [9]
0
0
Ryazan
Query!
Country [10]
0
0
Russian Federation
Query!
State/province [10]
0
0
Yaroslavl
Query!
Country [11]
0
0
United Kingdom
Query!
State/province [11]
0
0
Cambridgeshire
Query!
Country [12]
0
0
United Kingdom
Query!
State/province [12]
0
0
Lancashire
Query!
Country [13]
0
0
United Kingdom
Query!
State/province [13]
0
0
Merseyside
Query!
Country [14]
0
0
United Kingdom
Query!
State/province [14]
0
0
Northumberland
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
Oxford
Query!
Country [16]
0
0
United Kingdom
Query!
State/province [16]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is designed to compare a range of doses of SB-681323 with prednisolone, which has
known effects on rheumatoid arthritis patients. By comparing the two drugs and their effects
on blood proteins that indicate for rheumatoid arthritis, we hope to ascertain information on
the most effective dose of SB-681323 to use in future.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00134693
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00134693
Download to PDF